BeStock  
Stocks › Biotechnology › EWTX

Edgewise Therapeutics EWTX

US equityMarket cap rank #2154Biotechnology
$39.91 −$1.27 (-3.07%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $39.91 0.00%
Open$40.81
Prev close$41.17
Day range$39.71 – $41.41
Volume1.19M
Market cap$4.37B
P/E (TTM)4.8
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

EWTX at a glance

EWTX is priced at $39.91 right now, down 3.07% on the session. That puts its market value at $4.37B, 2154th largest among the 3753 stocks we cover.

Over a full year the shares have ranged across $19.76 to $48.78, which puts the current price roughly 69% of the way up that band. Holders are ahead 76.0% over twelve months, but down 10.8% across the last three months.

Price is below the 50-day average ($41.14) but above the 200-day ($37.34); RSI is 44, and the last 30 sessions moved at roughly 66% annualized volatility.

For the quarter ended Sep 2026 it reported $0.00 in revenue, with $1.17B of net profit.

Valuation works out to 4.8 times trailing earnings. The median for its industry group is 17.1.

10 analysts follow the stock and the average call is "buy". The mean target, $58.88, sits 47.6% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$29.87 / $41.76
Average price today$40.31
Volume1.19MAvg (90d) 1.44M
Turnover$47.83M
Turnover rate1.59%of shares outstanding
Volume ratio1.00vs. recent average pace
Day amplitude4.13%
Market cap$4.37B
Float market cap$2.98B
Shares outstanding74.58M
EPS (TTM)-$1.63
P/E (TTM)4.76
P/B2.68
Book value / share$14.91
Earnings yield21.00%
Net profit (TTM)-$178.46M
Net assets$1.63B
30-day volatility65.9%annualized
Avg daily range (ATR)8.34%of price, 14 days
Max drawdown (1y)-25.0%-18.1% from 1y peak

Quote as of Nov 22, 2026 5:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

D
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

F
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

C
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

10 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 66.2 · 2026-11-22 14:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation47.2
Growth—
Profitability5.4
Momentum80.7
Financial health99.6
Analyst view78.7

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$58.88+47.6% vs. current price
Consensus ratingBuy10 analysts covering
Morningstar fair value$41.85Close to fair value

Wall Street’s average 12-month target is $58.88, 47.6% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $41.85, so shares trade 4.7% below that estimate. On earnings multiple, it sits in the 100th percentile of its own five-year valuation range (pricier than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-3.1%
1 week
-13.1%
1 month
-0.2%
3 months
-10.8%
6 months
+22.0%
Year to date
+60.8%
1 year
+76.0%
Day range
$39.71$41.41
52-week range
$19.76$48.78

Technical signals

Full technicals →
Trend readLeaning bearish

2 bullish · 5 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average-4.6%Bearish
Price vs 50-day average-3.0%Bearish
Price vs 200-day average+6.9%Bullish
50-day vs 200-day50d above 200dBullish
RSI (14)44.2Bearish
MACD (12,26,9)0.52Bearish
Bollinger band position36%Bearish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How EWTX ranks on BeStock

Market value#2147 of 3734
P/E (cheapest = 1)#85 of 2917
Closeness to 52-week high#1323 of 3724
Dollar volume today#1451 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

Set against the peer table: at 4.8x earnings, EWTX looks cheap against the market, and trades 72% below the 17.1x median among Biotechnology names. The two comparisons do not always agree.

EWTX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on EWTX.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on EWTX

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

EWTX stock: common questions

How is Edgewise Therapeutics stock doing today?

$39.91 is the latest print for EWTX, a move of -3.07% against yesterday's close of $41.17. Today's low and high so far: $39.71 and $41.41.

How big is Edgewise Therapeutics?

Equity value comes to $4.37B at the current price. By that measure it is number 2154 of the 3753 names in our coverage.

Is EWTX expensive on earnings?

Buyers pay 4.8 times the last twelve months of profit (EPS $-1.63).

What's the 52-week trading range for Edgewise Therapeutics?

The year's floor is $19.76 and the ceiling $48.78. Shares are 18.2% away from that ceiling.

What's the dividend situation for EWTX?

Our data shows no dividend paid by Edgewise Therapeutics over the trailing twelve months.

What are analysts saying about EWTX?

Of 10 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $58.88, with the most cautious at $51.00 and the most optimistic at $85.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on EWTX.

Sign in to join the discussion.

Scroll to Top